Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
NCT01302886
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
41
Enrollment
INDUSTRY
Sponsor class
Conditions
Smoldering Multiple Myeloma
Interventions
DRUG:
BHQ880
Sponsor
Novartis Pharmaceuticals